{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:01:48Z","timestamp":1775617308621,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are effective routine treatments for colorectal peritoneal metastasis (PM). However, the safety and efficacy of neoadjuvant chemotherapy (NAC) before CRS+HIPEC are poorly understood. Therefore, this study aimed to assess the perioperative safety and long-term efficacy of NAC prior to CRS+HIPEC for patients with synchronous colorectal PM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with synchronous colorectal PM who received NAC prior to CRS+HIPEC were systematically reviewed at the China National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019. The clinicopathologic characteristics, perioperative parameters, and survival rates of patients who underwent CRS+HIPEC with NAC (NAC group) and patients who underwent CRS+HIPEC without NAC (non-NAC group) were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study enrolled 52 patients, with 20 patients in the NAC group and 32 in the non-NAC group. In the NAC group, the proportion of patients with a peritoneal carcinomatosis index (PCI) score &lt; 12 was significantly higher than that in the non-NAC group (80.0% vs 50.0%, <jats:italic>P<\/jats:italic> = 0.031), and more patients achieved complete cytoreduction (80.0% vs 46.9%, <jats:italic>P<\/jats:italic> = 0.018). The two groups had comparable grade III\/IV complications and similar reoperation and mortality rates (<jats:italic>P<\/jats:italic> &gt; 0.05). However, patients who received NAC had lower platelet counts (151.9 vs 197.7 \u00d7 10<jats:sup>9<\/jats:sup>\/L, <jats:italic>P<\/jats:italic> = 0.036) and neutrophil counts (4.7 vs 7.2 \u00d7 10<jats:sup>9<\/jats:sup>\/L, <jats:italic>P<\/jats:italic> = 0.030) on postoperative day 1. More patients survived for 2 years in the NAC group than in the non-NAC group (67.4% vs 32.2%, respectively, <jats:italic>P<\/jats:italic> = 0.044). However, the completeness of cytoreduction score (HR, 2.99; 95% CI, 1.14\u20137.84; <jats:italic>P<\/jats:italic> = 0.026), rather than NAC, was independently associated with overall survival (OS) in the multivariate analysis after controlling for confounding factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>NAC administration before CRS+HIPEC can be regarded as safe and feasible for patients with colorectal PM with comparably low mortality rates and acceptable morbidity rates. Nevertheless, large-sample randomized controlled studies are needed to confirm whether the administration of NAC before CRS+HIPEC confers a survival benefit to patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-021-02255-w","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:04:41Z","timestamp":1621281881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy"],"prefix":"10.1186","volume":"19","author":[{"given":"Sicheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2567-5429","authenticated-orcid":false,"given":"Jianwei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"2255_CR1","volume-title":"Colon Cancer. Version 2.2019","author":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology","year":"2019","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2019. 2019. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf (Accessed on 1 Nov 2019)."},{"issue":"4","key":"2255_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.canep.2014.04.004","volume":"38","author":"YR van Gestel","year":"2014","unstructured":"van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448\u201354. https:\/\/doi.org\/10.1016\/j.canep.2014.04.004.","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"2255_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/ijc.25596","volume":"128","author":"VE Lemmens","year":"2011","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717\u201325. https:\/\/doi.org\/10.1002\/ijc.25596.","journal-title":"Int J Cancer"},{"issue":"7","key":"2255_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/bjc.2013.82","volume":"108","author":"AG Kerscher","year":"2013","unstructured":"Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432\u20139. https:\/\/doi.org\/10.1038\/bjc.2013.82.","journal-title":"Br J Cancer"},{"issue":"12","key":"2255_CR5","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.ejso.2018.07.003","volume":"44","author":"M Bushati","year":"2018","unstructured":"Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44(12):1942\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2018.07.003.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2255_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2255_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(19)30239-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2255_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","volume":"36","author":"F Quenet","year":"2018","unstructured":"Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36:18.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2255_CR9","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1245\/s10434-018-6539-x","volume":"25","author":"NR Sluiter","year":"2018","unstructured":"Sluiter NR, Rovers KP, Salhi Y, Vlek SL, Coup\u00e9 VMH, Verheul HMW, et al. Metachronous peritoneal metastases after adjuvant chemotherapy are associated with poor outcome after cytoreduction and HIPEC. Ann Surg Oncol. 2018;25(8):2347\u201356. https:\/\/doi.org\/10.1245\/s10434-018-6539-x.","journal-title":"Ann Surg Oncol"},{"key":"2255_CR10","first-page":"1920276","volume":"2018","author":"A Sipok","year":"2018","unstructured":"Sipok A, Sardi A, Nieroda C, et al. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin-C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1920276.","journal-title":"Int J Surg Oncol"},{"issue":"4","key":"2255_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10151-020-02159-z","volume":"24","author":"C Agalar","year":"2020","unstructured":"Agalar C, Sokmen S, Arslan C, Altay C, Basara I, Canda AE, et al. The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience. Tech Coloproctol. 2020;24(4):301\u20138. https:\/\/doi.org\/10.1007\/s10151-020-02159-z.","journal-title":"Tech Coloproctol"},{"issue":"8","key":"2255_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/jso.25920","volume":"121","author":"MR Woeste","year":"2020","unstructured":"Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol. 2020;121(8):1298 published online ahead of print, 2020 Apr 1.","journal-title":"J Surg Oncol"},{"issue":"3","key":"2255_CR13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/jcm9030748","volume":"9","author":"EW Beal","year":"2020","unstructured":"Beal EW, Suarez-Kelly LP, Kimbrough CW, Johnston FM, Greer J, Abbott DE, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3):748. https:\/\/doi.org\/10.3390\/jcm9030748.","journal-title":"J Clin Med"},{"issue":"1","key":"2255_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12957-020-1784-4","volume":"18","author":"JSM Wong","year":"2020","unstructured":"Wong JSM, Tan GHC, Chia CS, Ong J, Ng WY, Teo MCC. The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2020;18(1):10. https:\/\/doi.org\/10.1186\/s12957-020-1784-4.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"2255_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/SLA.0b013e318255486a","volume":"256","author":"G Passot","year":"2012","unstructured":"Passot G, Vaudoyer D, Cotte E, You B, Isaac S, No\u00ebl Gilly F, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256(1):125\u20139. https:\/\/doi.org\/10.1097\/SLA.0b013e318255486a.","journal-title":"Ann Surg"},{"issue":"9","key":"2255_CR16","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1245\/s10434-014-3713-7","volume":"21","author":"W Ceelen","year":"2014","unstructured":"Ceelen W, Van Nieuwenhove Y, Putte DV, et al. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014;21(9):3023\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2255_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-018-1554-8","volume":"17","author":"M Leimk\u00fchler","year":"2019","unstructured":"Leimk\u00fchler M, Hemmer PHJ, Reyners AKL, de Groot DJA, van Ginkel RJ, Been LB, et al. Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study. World J Surg Oncol. 2019;17(1):14. https:\/\/doi.org\/10.1186\/s12957-018-1554-8.","journal-title":"World J Surg Oncol"},{"key":"2255_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"issue":"Suppl","key":"2255_CR19","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s002800051093","volume":"43","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43(Suppl):S15\u201325. https:\/\/doi.org\/10.1007\/s002800051093.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2255_CR20","first-page":"461","volume":"42","author":"S Hamashige","year":"2008","unstructured":"Hamashige S, Arquilla ER. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Principles Pract Clin Trial Med. 2008;42(4):461\u2013533.","journal-title":"Principles Pract Clin Trial Med"},{"issue":"12","key":"2255_CR21","doi-asserted-by":"publisher","first-page":"12099","DOI":"10.2147\/CMAR.S281434","volume":"24","author":"W Pei","year":"2020","unstructured":"Pei W, Zhou S, Zhang J, et al. Lobaplatin-based hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastasis from appendiceal and colorectal cancer: safety and efficacy profiles. Cancer Manag Res. 2020;24(12):12099\u2013110.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"2255_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1245\/s10434-010-1522-1","volume":"18","author":"TC Chua","year":"2011","unstructured":"Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18(6):1560\u20137. https:\/\/doi.org\/10.1245\/s10434-010-1522-1.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2255_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e3181a45d86.","journal-title":"Ann Surg"},{"issue":"9","key":"2255_CR24","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1245\/s10434-016-5214-3","volume":"23","author":"RA Devilee","year":"2016","unstructured":"Devilee RA, Simkens GA, van Oudheusden TR, Rutten HJ, Creemers GJ, ten Tije AJ, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2841\u20138. https:\/\/doi.org\/10.1245\/s10434-016-5214-3.","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"2255_CR25","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, de Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392. https:\/\/doi.org\/10.1200\/JCO.2004.10.012.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2255_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.9285.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02255-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:07:29Z","timestamp":1621282049000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02255-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2255"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02255-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The ethics committee of the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College approved this study. Prior written informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"151"}}